BGNE Stock Overview
An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
BeiGene, Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$194.26 |
| 52 Week High | US$248.16 |
| 52 Week Low | US$126.97 |
| Beta | 0.63 |
| 11 Month Change | -11.67% |
| 3 Month Change | -0.70% |
| 1 Year Change | 6.28% |
| 33 Year Change | -44.74% |
| 5 Year Change | -4.89% |
| Change since IPO | 585.95% |
Recent News & Updates
Recent updates
BeiGene: TEVIMBRA European Push Continues With Positive CHMP Opinion
Nov 06BeiGene: Poised For Re-Rating As BTKi Sales Show Strong Beat
Aug 22Analysts Just Made An Incredible Upgrade To Their BeiGene, Ltd. (NASDAQ:BGNE) Forecasts
Aug 14
BeiGene, Ltd. (NASDAQ:BGNE) Shares Fly 27% But Investors Aren't Buying For Growth
Aug 09BeiGene: Navigating Patent Disputes Towards Profitability (Rating Upgrade)
Jun 21We Think Some Shareholders May Hesitate To Increase BeiGene, Ltd.'s (NASDAQ:BGNE) CEO Compensation
May 30Is BeiGene (NASDAQ:BGNE) Using Too Much Debt?
Apr 21BeiGene Still Bleeding Red Ink Despite Blockbuster Drug
Mar 08BeiGene, Ltd.'s (NASDAQ:BGNE) Intrinsic Value Is Potentially 26% Above Its Share Price
Jan 31Here's Why BeiGene (NASDAQ:BGNE) Can Manage Its Debt Despite Losing Money
Oct 16Is There An Opportunity With BeiGene, Ltd.'s (NASDAQ:BGNE) 39% Undervaluation?
Jul 11Rock star Growth Puts BeiGene (NASDAQ:BGNE) In A Position To Use Debt
Jun 19Revenues Not Telling The Story For BeiGene, Ltd. (NASDAQ:BGNE)
Apr 17A Look At The Fair Value Of BeiGene, Ltd. (NASDAQ:BGNE)
Mar 24Shareholder Returns
| BGNE | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.6% | -7.5% | -1.2% |
| 1Y | 6.3% | 14.1% | 30.4% |
Return vs Industry: BGNE underperformed the US Biotechs industry which returned 14.1% over the past year.
Return vs Market: BGNE underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| BGNE volatility | |
|---|---|
| BGNE Average Weekly Movement | 5.6% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BGNE has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BGNE's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 10,000 | John Oyler | www.beigene.com |
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. The company’s clinical stage products comprise BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; BGB-10188; BGB-21447, a Bcl-2 inhibitor; Ociperlimab (BGB-A1217), a TIGIT inhibitor; Zanidatamab, a bispecific HER2-targeted antibody; Surzebiclimab (BGB-A425), a TIM-3 inhibitor; BGB-A445, an OX40 agonist antibody; BGB-15025, a small molecule inhibitor of HPK1; BGB-24714, a SMAC mimetic; BGB-26808, a HPK-1 inhibitor; Lifirafenib and BGB-3245 that are inhibitors of RAF; BGB-30813; BGB-A3055, an anti-CCR8 antibody; and BGB-43395, a CDK-4 inhibitor.
BeiGene, Ltd. Fundamentals Summary
| BGNE fundamental statistics | |
|---|---|
| Market cap | US$19.95b |
| Earnings (TTM) | -US$827.13m |
| Revenue (TTM) | US$3.24b |
6.4x
P/S Ratio-25.0x
P/E RatioIs BGNE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BGNE income statement (TTM) | |
|---|---|
| Revenue | CN¥23.51b |
| Cost of Revenue | CN¥3.84b |
| Gross Profit | CN¥19.67b |
| Other Expenses | CN¥25.66b |
| Earnings | -CN¥5.99b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -56.41 |
| Gross Margin | 83.67% |
| Net Profit Margin | -25.50% |
| Debt/Equity Ratio | 29.6% |
How did BGNE perform over the long term?
See historical performance and comparison